Try our Advanced Search for more refined results

Cancer Drug Kadcyla Must Be Called By Full Name, FDA Says

By Daniel Wilson (May 6, 2013, 4:31 PM EDT) -- The U.S. Food and Drug Administration on Monday urged health care professionals and publications to use the full generic name of Genentech Inc.'s breast cancer treatment Kadcyla when referring to the drug, saying use of a truncated name could lead to harmful confusion with another treatment....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!